methadone in management of opioid (opiate) abuse
Last edited 05/2023 and last reviewed 05/2023
Methadone is a synthetic compound with pharmacologic action similar to that of morphine and heroin, almost equal in addiction liability.
The hydrochloride is used as an antitussive and analgesic and as a substitute narcotic in the management of opiate withdrawal, since it is longer acting than most opiates.
It is substituted for an abused opiate and then the dose is reduced.
- methadone is available as an oral solution (1 mg/ml), an oral concentrate (10 mg/ml), tablets or injectable ampoules
- methadone has a long elimination half-life (usually 20-37 hours), which allows for a once-daily dosing schedule
- methadone appears to have no serious long-term side effects associated with chronic administration (1)
- in the context of opioid dependence management, and using a methadone maintenance regimen, the drug does not have the pronounced narcotic effects seen with shorter-acting opioids such as illicit diamorphine
- interactions with
other drugs
- elimination of methadone is increased by some drugs including including rifampicin, phenytoin, phenobarbital and some antiviral drugs used in the treatment of HIV infection
- rate of elimination is reduced by drugs such as fluvoxamine and fluoxetine
Conult the Summary of Product Characteristics before prescribing this drug.
Notes:
- methadone
or buprenorphine should be offered as the first-line treatment in opioid detoxification.
When deciding between these medications, healthcare professionals should take
into account (2):
- whether the service user is receiving maintenance treatment with methadone or buprenorphine; if so, opioid detoxification should normally be started with the same medication
- the preference of the service user
- a review of 83 RCTs & 193 observational studies (total > 1 million participants) found, at timepoints beyond 1 month, retention in treatment was better for methadone vs buprenorphine (3)
- also found evidence of reduced cocaine use, cravings, anxiety, and cardiac dysfunction, as well as increased treatment satisfaction among people receiving buprenorphine compared with methadone
- evidence of reduced hospitalisation and alcohol use in people receiving methadone
- note though that most comparisons were based on small numbers of studies
Reference:
- NICE (January 2007).Methadone and buprenorphine for the management of opioid dependence
- NICE (July 2007).Drug misuse - Opioid detoxification
- Degenhardt L et al. Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies. Lancet Psychiatry May 8th 2023.
methadone: dosage and conversion
choosing between buprenorphine and methadone in the treatment of opioid dependence
methadone and prolongation of QT interval
NICE guidance - methadone and buprenorphine for the management of opioid (opiate) dependence
opioid (opiate) detoxification